Information on blinding in registered records of clinical trials. by Viergever, Roderik F & Ghersi, Davina
Viergever, RF; Ghersi, D (2011) The ClinicalTrials.gov Results Database.
The New England journal of medicine, 364 (22). pp. 2169-2170. ISSN
0028-4793
Downloaded from: http://researchonline.lshtm.ac.uk/544/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
correspondence
n engl j med 364;22 nejm.org june 2, 2011 2169
2. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized 
investigation of high-dose versus standard-dose cytosine arabi-
noside with daunorubicin in patients with previously untreated 
acute myeloid leukemia: a Southwest Oncology Group study. 
Blood 1996;88:2841-51.
3. Bradstock KF, Matthews JP, Lowenthal RM, et al. A random-
ized trial of high-versus conventional-dose cytarabine in consoli-
dation chemotherapy for adult de novo acute myeloid leukemia 
in first remission after induction therapy containing high-dose 
cytarabine. Blood 2005;105:481-8.
4. Büchner T, Berdel WE, Schoch C, et al. Double induction 
containing either two courses or one course of high-dose cytar-
abine plus mitoxantrone and postremission therapy by either 
autologous stem-cell transplantation or by prolonged mainte-
nance for acute myeloid leukemia. J Clin Oncol 2006;24:2480-9.
5. Moore JO, George SL, Dodge RK, et al. Sequential multi-
agent chemotherapy is not superior to high-dose cytarabine 
alone as postremission intensification therapy for acute myeloid 
leukemia in adults under 60 years of age: Cancer and Leukemia 
Group B Study 9222. Blood 2005;105:3420-7.
The ClinicalTrials.gov Results Database
To the Editor: Zarin et al. (March 3 issue)1 pro-
vide an update on ClinicalTrials.gov, currently the 
only publicly available database reporting trial 
results; it should be used in systematic reviews 
and meta-analyses. Of the researchers who wrote 
more than 12,000 such reviews and meta-analy-
ses published and indexed in PubMed between 
2009 and 2010, less than 2% reported using 
ClinicalTrials.gov to search for unpublished data.2 
The scarce utilization suggests the scientific com-
munity is not sufficiently aware of ClinicalTrials 
.gov or else struggles with implementation of this 
key resource for synthesis of research.
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To the Editor: We report an experience with 
ClinicalTrials.gov and our international random-
ized, controlled trial CHIPS (Control of Hyper-
tension In Pregnancy Study). CHIPS is funded by 
the Canadian Institutes of Health Research, which 
mandates registration and assignment of an Inter-
national Standard Randomised Controlled Trial 
Number (ISRCTN) (no. 71416914). However, one 
of our active international sites discovered that 
CHIPS had been registered on ClinicalTrials.gov 
by another interested (but not active) site. The 
ClinicalTrials.gov entry contained many factual 
errors. Although we have now overridden this 
submission, is there a mechanism to prevent du-
plicate and inaccurate registration?
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To the Editor: There are considerable disincen-
tives to the reporting requirement in ClinicalTrials 
.gov. Three examples include the fact that all data 
entry has to be performed manually rather than 
being uploaded with the use of commonly used 
software programs and formats such as Micro-
soft Word, Adobe Portable Document Format 
(PDF), Microsoft Excel, or SAS statistical software. 
Another problem is that the different measures 
of “dispersion” (e.g., standard error, standard de-
viation, 95% confidence interval, and interquar-
tile range) within studies add complexity to data 
entry in various tables. Finally, the space allotted 
to specific sections (e.g., statistical analysis) is 
insufficient.
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To the Editor: ClinicalTrials.gov has important 
quality-control measures to prevent information 
in registered records from being omitted, incom-
plete, incorrect, or uninformative. Unfortunately, 
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the quality of registered trial data across regis-
tries remains a problem. Using one of the criteria 
proposed by Zarin et al., we identified “internal 
inconsistency” as a problem in about 9% of rec-
ords in the World Health Organization (WHO) 
International Clinical Trials Registry Platform 
(ICTRP) search portal.1 In the records for these 
trials, multiple descriptors that are not compati-
ble — such as “single-group” and “controlled or 
randomized”; “open-label” and “blinded”; and 
“double-blinded without subject or investigator 
blinding” — were used.
The ICTRP has now established International 
Standards for Clinical Trial Registries, which set 
a minimum requirement for quality-control pro-
cesses performed and data recording practices 
used by individual registries. The intention is to 
implement these minimum standards and mon-
itor compliance by registries in the WHO Regis-
try Network to ultimately achieve the recording 
of more complete and meaningful clinical-trial 
information.
Roderik F. Viergever, M.D.
London School of Hygiene and Tropical Medicine 
London, United Kingdom
Davina Ghersi, M.P.H., Ph.D.
World Health Organization  
Geneva, Switzerland 
ghersid@who.int
Dr. Ghersi reports being the team leader of the International 
Clinical Trials Registry Platform of the World Health Organiza-
tion. No other potential conflict of interest relevant to this letter 
was reported.
1. Viergever RF, Ghersi D. The quality of registration of clinical 
trials. PLoS ONE 2011;6(2):e14701.
The Authors Reply: We agree with Wyler von 
Ballmoos and Oliveira that ClinicalTrials.gov is 
an important resource for systematic reviewers 
as well as for anybody else (e.g., members of in-
stitutional review boards) who seeks the com-
plete evidence base on a given topic. Since the 
results of many clinical trials remain unpub-
lished,1 even years after completion, it is clear 
that a literature search alone will not result in a 
complete picture of the evidence.
Magee and Menzies raise the issue of dupli-
cate and inaccurate registrations. We previously 
addressed the importance of preventing duplicate 
registrations and ensuring the accuracy of reg-
istrations.2 To prevent unintended duplicate reg-
istrations, the sponsor, study sites, and all relevant 
parties must identify the one person who will be 
responsible for trial-registration and related re-
porting activities; that person would be designat-
ed as the responsible party in ClinicalTrials.gov. 
Individual study-site investigators should not reg-
ister their study unless they serve as the respon-
sible party for the overall trial. If a study must 
be submitted to multiple registries (e.g., to com-
ply with regional policies), we ask that the NCT 
number and other registry identifiers be listed in 
all registrations to allow for the identification of 
(intentional) duplicate records. Regarding inaccu-
racies, although our staff manually reviews each 
record, certain factual errors cannot be detected 
without access to the study data. It is essential 
that the responsible party has the necessary ex-
pertise to submit accurate and informative data.
Camilleri notes that ClinicalTrials.gov does 
not allow for the uploading of data in formats 
used by popular software platforms. However, 
ClinicalTrials.gov does support the uploading of 
data in the Extensible Markup Language (XML) 
format, a standard method of encoding informa-
tion in an unambiguous machine-readable struc-
ture — unlike the data-file formats mentioned by 
Camilleri. Without the structured numeric entries 
afforded by the XML format, it would not be 
possible for the ClinicalTrials.gov system to per-
form automated validation of entries or to provide 
consistent displays of data.
We agree with Viergever and Ghersi that reg-
istries must implement quality-control measures. 
However, the quality of entries will always be 
dependent on the diligence and integrity of the 
person entering the data.
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